The recent identification of JMJD6–IL-4 axis as a novel regulator of oral CSCs is of particular interest given the plausibility that novel treatments targeting JMJD6 could be an effective treatment modality for oral cancer. The gene discussed is JMJD6; the disease is lip and oral cavity carcinoma.